|
|
|
|
|
Twitter
IASLC EGFR, NSCLC, JTOCRR, LCSM: 22/06/2021 14:01:06
|
|
|
|
Horn et al. evaluated the content validity, clarity, and relevance of two patient reported outcomes for use in adults with #EGFR mutated #NSCLC https://t.co/ybwMnvvjjT @JTOonline @OncologyAdvance #JTOCRR #LCSM
Read more
|
|
|
|
|
|
|
|
|
Twitter
JTO & JTO CRR EGFR, NSCLC, JTOCRR, LCSM: 22/06/2021 14:02:16
|
|
|
|
Horn et al. evaluated the content validity, clarity, and relevance of two patient reported outcomes for use in adults with #EGFR mutated #NSCLC https://t.co/WNOP3sz5OX @IASLC @OncologyAdvance #JTOCRR #LCSM
Read more
|
|
|
|
|
|
|
|
|
Twitter
JanssenUS BREAKING, NSCLC, EGFR, lcsm: 22/06/2021 21:36:56
|
|
|
|
#BREAKING: Updated recommendation in V.5.2021 of the NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesĀ®) @JNCCN non-small cell lung cancer (#NSCLC) with #EGFR exon 20 insertion mutations #lcsm https://t.co/iPHEvh1qt1
Read more
|
|
|
|
|
|
|
|
|
Twitter
NCI Systems Biology NCICSBC, NSCLC, immunotherapy, CIM21: 22/06/2021 12:07:03
|
|
|
|
Researchers @MoffittResearch #NCICSBC are studying the evolutionary and ecological dynamics that govern response and resistance of non-small cell lung cancer (#NSCLC) to #immunotherapy: https://t.co/9rlskdj0fA #CIM21
Read more
|
|
|
|
|
|
|
|
|
Twitter
Journal of Molecular Pathology MDPI Clinical_Trial, Lung_Cancer, immunotherapy, targeted_therapy, NSCLC: 23/06/2021 07:25:35
|
|
|
|
New paper šModern Challenges for Early-Phase #Clinical_Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell #Lung_Cancer
#immunotherapy #targeted_therapy #NSCLC
šhttps://t.co/tdORTNuKcK
Read more
|
|
|
|
|
|
|
|
|
Twitter
Research Square Preprints preprints: 22/06/2021 15:35:07
|
|
|
|
Causal Relationship between Postoperative Recurrence and PD-L1 and EGFR Mutations in NSCLC: A Retrospective Cohort Study #preprints
Read more
|
|
|
|
|
|
|
|
|
Twitter
Sandy Anderson : 22/06/2021 15:55:26
|
|
|
|
A truly integrated new study from board to bench to bedside by Franziska Michor and led by Kamrine Poels: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant NSCLC @NatureComms
Read more
|
|
|
|
|
|
|
|
|
Twitter
Oncology Publishers Feed Oncology, MedTwitter, MedEd: 22/06/2021 18:36:03
|
|
|
|
Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC
More medical news at https://t.co/DUWSlWzJcW
#Oncology #MedTwitter #MedEd
Read more
|
|
|
|
|
|
|
|
|
Twitter
ASCO Publications EGFR, RET, BRAF, lcsm, JCOPO: 22/06/2021 20:10:02
|
|
|
|
Using serial cfDNA @StephenVLiu et al. describe a case of divergent acquired resistance to osimertinib in #EGFR+ NSCLC mediated by #RET fusion and simultaneous #BRAF V600E mutation https://t.co/tJBTsL6xly #lcsm #JCOPO
Read more
|
|
|
|
|
|
|
|
|
Twitter
Targeted Oncology LCSM: 23/06/2021 00:00:42
|
|
|
|
Treatment of patients with EGFR-mutant nonāsmall cell lung cancer in the phase 3 ADAURA clinical trial resulted in practice-changing disease-free survival with tolerable safety. #LCSM
Read more
|
|
|
|
|
|
|
|
|
Twitter
Wellcome-home : 23/06/2021 00:15:28
|
|
|
|
(Clinical Challenge: Optimal Therapies for Rare EGFR Mutations in NSCLC) has been published on chineselgz -
Read more
|
|
|
|
|
|
|
|
|
Twitter
TYR Kinase papers : 23/06/2021 03:09:02
|
|
|
|
PKCĪ“-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs
Read more
|
|
|
|
|
